ecancermedicalscience

Clinical Study

Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year

17 Mar 2016
Carmen Herrero-Vicent, Isidro Machado, Carmen Illueca, Amparo Avaria, Claudia Salazar, Abraham Hernandez, Sergio Sandiego, Javier Lavernia

Mantle cell lymphoma (MCL) is an infrequent subtype of non-Hodgkin’s lymphoma (NHL) and represents between 4–8% of adult lymphomas. Recently an increase in its incidence to 1–2 cases/100,000 inhabitants/year has been observed. The first line of treatment is based on chemoimmunotherapy and depends on age and the initial stage at diagnosis. There are no second line or successive treatments. There are currently several drugs available that provide acceptable results.

Related Articles

Hafssa El Hilali, Nassiba Bahra, Sanae Guennouni, Chaymae Chbihi, Samia El Hakym, Diango Keita, Sara Nejjari, Abir Oufrid, Oumaima Siyouri, Lamiae Amaadour, Karima Oualla, Zineb Benbrahim, Touria Bouhafa, Nawfel Mellas, Samira El Fakir, Samia Arifi
Hugo Castro-Salguero, Bremilin Ramírez-Najarro, Jorge Tello-Mérida, Lourdes Castro-Salazar, Luis García-Aceituno
Marc Hendricks, Helen Meintjes, Joyce Balagadde Kambugu, Vivian Paintsil, George Chagaluka, Lawrence Osei-Tutu, Esther Majaliwa, Loyce Hlatywayo, Motunrayo Adekunle, Katlego Tsimane, Beatrice Chikaphonya-Phiri, Emmanuella Amoako, Mamiki Chise, Stella Mzumara, Linda Kissila, Yaa Gyamfua Oppong-Mensah, Tumweneni Mekelaye Nghaamwa, Jaques van Heerden, Helder de Quintal, Alan Davidson
Daniel F Pilco-Janeta, Myriam De la Cruz-Puebla, Daisy Guamán-Pilco, Diego Montenegro, Philipp Novotny, William Miranda